Stock 600267 ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Zhejiang Hisun Pharmaceutical Co., Ltd.

Equities

600267

CNE0000013Z2

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
8.16 CNY +3.29% Intraday chart for Zhejiang Hisun Pharmaceutical Co., Ltd. +9.68% -12.82%
Apr. 29 Zhejiang Hisun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 29 Zhejiang Hisun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Zhejiang Hisun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Zhejiang Hisun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Tranche Update on Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on December 23, 2023.
CI
Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback announced on December 23, 2023, has closed with 11,687,200 shares, representing 0.98% for CNY 98.99 million.
CI
Hisun Pharma's Unit Gets Nod for Pig Vaccine
MT
Tranche Update on Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on December 23, 2023.
CI
China Energy Engineering Issues Apology Over Former Director's Stake Disposal Breaches
MT
Tranche Update on Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on December 23, 2023.
CI
Zhejiang Hisun Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.
CI
Zhejiang Hisun Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
CI
Hisun Pharmaceutical's Unit Gets Certification for Imported Drug from Pfizer
MT
Hisun Pharmaceutical's Unit Gets Import Drug Certificate for Methylprednisolone Tablets
MT
Hisun Pharmaceutical's Unit Gets Nod for Carprofen Tablets for Dogs
MT
Zhejiang Hisun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Hisun Pharmaceutical Gets China Nod to Market Cytarabine
MT
Tranche Update on Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on September 22, 2022.
CI
Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback announced on September 22, 2022, has closed with 18,489,100 shares, representing 1.55% for CNY 194.73 million.
CI
Shanghai Shyndec Pharma Gets Nod to Market Blood Sugar Drug Ingredient
MT
Zhejiang Hisun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Hisun Pharmaceutical Gets European Certificate for Veterinary Drug Ingredient
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 600267 Stock
  4. News Zhejiang Hisun Pharmaceutical Co., Ltd.
  5. Highlights